Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

5.250 USD -0.060 (-1.13%)
Streaming Delayed Price Updated: 8:29 AM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Genprex Inc

< Previous 1 2 3 4 5 6 7 Next >
Proactive news headlines including Tocvan Ventures, HempFusion Wellness, Milestone Scientific and Esports Entertainment Group
Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: 
From GlobeNewswire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering
From InvestorBrandNetwork
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants 
From Business Wire News Releases
Genprex Announces Formation of Clinical Advisory Board
Genprex forms a Clinical Advisory Board. 
From Business Wire News Releases
Small and Microcap Company Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations 
From PR Newswire
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day
From InvestorBrandNetwork
Genprex Recognizes World Cancer Day
Genprex honors World Cancer Day. 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Issues Shareholder Letter, Corporate Update
From InvestorBrandNetwork
Genprex Issues Shareholder Letter and Provides Corporate Update
Genprex issues January 2021 shareholder letter. 
From Business Wire News Releases
Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th
Company executives will share vision and answer audience questions at VirtualInvestorConferences.com 
From PR Newswire
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present at Upcoming Virtual Investor Conference Small and Microcap Showcase
From InvestorBrandNetwork
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
Genprex's CEO will present on February 4 at the Virtual Investor Conference. 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present Trailblazing Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
From InvestorBrandNetwork
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
Genprex's CEO will present at the MoneyShow Virtual Conference on January 28. 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17
From InvestorBrandNetwork
Genprex to Present at NobleCon17 on January 19
Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment
From InvestorBrandNetwork
Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures $12M in Registered Direct Offering
From InvestorBrandNetwork
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants
Genprex announces $12 million registered direct closing. 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement
From InvestorBrandNetwork
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants
Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it... 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Reaches Another Significant Milestone with Scaled-up Production of Clinical-Grade REQORSA(TM)
From InvestorBrandNetwork
Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer
Genprex completes clinical-grade manufacturing of lead drug candidate, REQORSA 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Finalizes Technology Transfer of Manufacturing Process for Novel Gene Therapy
From InvestorBrandNetwork
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
Genprex completes major manufacturing milestone with completion of technology transfer 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Overview, Clinical Trial Update at Upcoming Benzinga Conference
From InvestorBrandNetwork
Genprex to Present at the Benzinga Global Small Cap Conference on December 8
Genprex's President and CEO will present at the Benzinga Conference on Dec. 8, 2020 at 2:30 p.m. ET 
From Business Wire News Releases
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Upcoming Acclaim-1 Clinical Trial
From InvestorBrandNetwork
Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Genprex commences clinical trial site recruitment for Acclaim-1 clinical trial 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.